← Leaderboards
Naris Nilubol
Division Of Basic Sciences - Nci
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at Division Of Basic Sciences - Nci
Same institution · by research overlap
Others in their field
Top investigators on “Malignant Neoplasm Of Thyroid”
- David Heimbrook · Leidos Biomedical Research, Inc.$89,819,252
- James A Fagin · Sloan-Kettering Inst Can Research$18,343,965
- Keri Hammel · The Emmes Company, Llc$17,992,237
- Stanley R Hamilton · Johns Hopkins University$17,360,724
- Larry Arthur$15,377,757
- Ignacio I. Wistuba · Ut Southwestern Medical Center$15,303,923
Research focus
Malignant Neoplasm Of ThyroidSurvivorsNovel Anticancer DrugMalignant NeoplasmsCellsStrategic PlanningMalignant Endocrine Gland NeoplasmMolecular Targeted TherapiesTherapeutic TargetAnaplastic Thyroid CancerTumorApoptosisFamilyCancer CareAdrenocortical CarcinomaCancer PatientQuality Of LifeCaspasePharmaceutical PreparationsComputerizedAuranofinCancer CellCell ProliferationGold
Grant awards (7)
Therapeutic targets and novel anticancer agents for endocrine cancers$926,461
ZIA · FY2025 · CA · contact PI
Therapeutic targets and novel anticancer agents for endocrine cancers$802,871
ZIA · FY2024 · CA · contact PI
Therapeutic targets and novel anticancer agents for endocrine cancers$891,488
ZIA · FY2023 · CA · contact PI
Therapeutic targets and novel anticancer agents for endocrine cancers$1,360,206
ZIA · FY2022 · CA · contact PI
Therapeutic targets and novel anticancer agents for endocrine cancers$1,254,239
ZIA · FY2021 · CA · contact PI
Therapeutic targets and novel anticancer agents for endocrine cancers$1,506,202
ZIA · FY2020 · CA · contact PI
Therapeutic targets and novel anticancer agents for endocrine cancers$964,757
ZIA · FY2019 · CA · contact PI